Clinical Trials List
2019-12-01 - 2025-06-16
Phase III
Terminated4
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- MING YAO Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- HSIN-AN HOU Division of General Internal Medicine
- 劉家豪 Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
- - - Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- - - Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- Sheng-chieh Chou Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Tung-Liang Lin Division of Hematology & Oncology
- 歐哲瑋 Division of Hematology & Oncology
- Po-Nan Wang Division of Hematology & Oncology
- Hung Chang Division of Hematology & Oncology
- 高小雯 Division of Hematology & Oncology
- 蘇羿囷 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chi-Ching Chen Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Jeng-Shiun Du Division of Hematology & Oncology
- Tsung-Jang Yeh Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- 高育青 Division of Hematology & Oncology
- 唐世豪 Division of Hematology & Oncology
- Shih-Feng Cho Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
360 participants
